Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) SVP William E. Rote sold 5,200 shares of the company's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total transaction of $122,356.00. Following the sale, the senior vice president now directly owns 98,519 shares of the company's stock, valued at approximately $2,318,152.07. This trade represents a 5.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Travere Therapeutics Stock Performance
TVTX stock traded down $0.81 during mid-day trading on Friday, hitting $22.91. The stock had a trading volume of 1,466,790 shares, compared to its average volume of 1,303,585. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $25.29. The firm has a fifty day simple moving average of $19.22 and a 200 day simple moving average of $16.14.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on TVTX shares. Cantor Fitzgerald started coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating on the stock. Wells Fargo & Company upgraded shares of Travere Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Scotiabank increased their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a report on Wednesday. Barclays increased their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 1st. Finally, Piper Sandler raised their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a "neutral" rating in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, Travere Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $27.77.
Check Out Our Latest Stock Analysis on Travere Therapeutics
Institutional Investors Weigh In On Travere Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Rock Springs Capital Management LP boosted its stake in shares of Travere Therapeutics by 6.2% in the 4th quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company's stock valued at $86,641,000 after purchasing an additional 289,173 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Travere Therapeutics by 28.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company's stock worth $41,974,000 after purchasing an additional 534,500 shares during the period. Emerald Advisers LLC lifted its position in shares of Travere Therapeutics by 8.4% in the 4th quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company's stock worth $37,030,000 after purchasing an additional 165,085 shares during the period. Geode Capital Management LLC increased its stake in shares of Travere Therapeutics by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 1,842,301 shares of the company's stock valued at $32,100,000 after acquiring an additional 111,256 shares in the last quarter. Finally, Finepoint Capital LP increased its stake in shares of Travere Therapeutics by 0.3% in the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company's stock valued at $24,934,000 after acquiring an additional 5,539 shares in the last quarter.
About Travere Therapeutics
(
Get Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Read More
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
